Trials / Completed
CompletedNCT06098027
Study of [14C]CS0159 in China Healthy Subjects
[14C]CS0159 in Chinese Healthy Subjects for Mass Balance Phase I Study
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Cascade Pharmaceuticals, Inc · Academic / Other
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Study of \[14C\]CS0159 in China Healthy Subjects.
Detailed description
A phase I study to quantify the total mass balance in healthy subjects after a single dose of \[14C\]CS0159.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]CS0159 | Single oral administration of 4mg \[14C\]CS0159 |
Timeline
- Start date
- 2023-10-23
- Primary completion
- 2023-11-02
- Completion
- 2023-11-02
- First posted
- 2023-10-24
- Last updated
- 2023-11-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06098027. Inclusion in this directory is not an endorsement.